SAB Biotherapeutics Inc (SABS) Stock Price, Quote, News & History

SABSNASDAQ
$3.88
-0.005-0.13%
Last update: Aug 27, 10:48 AM
40%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-53.94M
Investing Cash Flow (TTM)
-202.11M
Financing Cash Flow (TTM)
260.93M
Free Cash Flow (TTM)
-57.44M
Capital Expenditure (TTM)
-
Net Change in Cash (TTM)
4.89M

Analyst Trends and Forecast

2
Mar
1
Apr
4
May
4
Jun
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$254.62M
PE Ratio (TTM)
16.13
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
-
PB Ratio (TTM)
1.64
Earnings Yield % (TTM)
6.20%
Earnings Yield % (FWD)
-30.23%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$2.36

Company Debt

Total Debt
-
LT Debt
-
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
$127.44K
Total Cash
$8.27M
Debt to Equity
0.02
Issuance of Debt (TTM)
$127.44K
Repayment of Debt (TTM)
-$148.41K

Key Statistics

Open
$3.86
Close
-
Volume / Avg.
32.79K / 662.66K
Day Range
$3.84 - $3.90
52 Wk Range
1.85 - 5.15
Market Cap
$352.57M
P/E Ratio
16.13
Dividend Yield
-
Exchange
NASDAQ
RSI
56
Short Interest
5.25%
Days to Cover
11

About

Sector
Health Care
Industry
Biotechnology
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-14...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy SAB Biotherapeutics (SABS) stock?

A

You can purchase shares of SAB Biotherapeutics (NASDAQ:SABS) through any online brokerage.

View our list of the best stock brokerages

Q

Who are SAB Biotherapeutics (SABS) competitors?

Q

What is the forecast, or price target, for SAB Biotherapeutics (SABS) stock?

A

SAB Biotherapeutics has a consensus price target of $10.86.

Q

What is the current price for SAB Biotherapeutics (SABS)?

A

The stock price for SAB Biotherapeutics (NASDAQ: SABS) is $3.875 last updated August 27, 2026 at 10:48 AM EDT.

Q

Does SAB Biotherapeutics (SABS) pay a dividend?

A

There are no upcoming dividends for SAB Biotherapeutics.

Q

When is SAB Biotherapeutics (NASDAQ:SABS) reporting earnings?

A

SAB Biotherapeutics does not have any upcoming earnings scheduled.

Q

Is SAB Biotherapeutics (SABS) going to split?

A

There is no upcoming split for SAB Biotherapeutics.

Q

What sector and industry does SAB Biotherapeutics (SABS) operate in?

A

SAB Biotherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.